Key Insights

Highlights

Treatment Research

4 treatments under study, led by Aflibercept

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 55/100

Termination Rate

100.0%

1 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Terminated1

Clinical Trials (1)

Showing 1 of 1 trials
NCT03845049Phase 3Terminated

Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1

Showing all 1 trials

Research Network

Common Treatments

  • Aflibercept1
  • Inclusion Examinations1
  • Examinations During Study Every Month1
  • Sham Injection1

Active Sponsors

  • Centre Hospitalier Universitaire De Dijon1
  • Centre Hospitalier Universitaire Dijon1

Related Conditions

  • Macular Telangiectasia1

Activity Timeline